Can a lab technique mature eggs more gently for IVF?

NCT ID NCT07789730

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This pilot trial tests CAPA-IVM, a two-step laboratory process that matures eggs after they are retrieved, as an option for people with good ovarian reserve who need fertility treatment. Researchers will check how many eggs reach maturity, how many fertilize, and whether the method is practical. The study includes about 40 participants aged 18 to 37 with healthy egg supply. The goal is to see if this approach can support pregnancy with less hormone stimulation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CAPA-IVM, a two-step laboratory process to mature eggs after retrieval
What this could lead to
If it works, CAPA-IVM could offer a gentler, hormone-sparing way to mature eggs in the lab and help more people with good ovarian reserve achieve pregnancy.
What could go wrong
This is a small pilot study, so success is not guaranteed. The approach may not improve pregnancy rates, and risks include fertilization or embryo development issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 37 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed Informed Consent Form to participate in this study voluntarily. 2. Age 18-37 years at the time of starting the CAPA-IVM cycle. 3. Body mass index (BMI) ≤38 kg/m2. 4. Serum AMH levels greater than or equal to 3.5 ng/mL. 5. Have an indication for IVM/IVF cycle. 6. Have not received more than two previous treatments of IVM/IVF. 7. Willing and able to comply with trial procedures, including oocyte pick-up from small follicles and to follow a CAPA-IVM cycle. 8. Agree to culture all embryos to blastocyst stage, vitrify suitable blastocysts, and submit suitable blastocysts for PGT-A according to clinic protocol before determining transfer eligibility. 9. Agree that only euploid CAPA-IVM-derived blastocysts will be eligible for transfer and that a single euploid blastocyst will be transferred per programmed FET cycle, unless a protocol-defined exception is prospectively justified by the investigator. Exclusion Criteria: 1. Prior ovarian surgery. 2. Known uterine abnormalities (adenomyosis, leiomyoma (≥5 cm), bicornuate uterus, intrauterine adhesion) that would compromise successful pregnancy or live birth. 3. Had received ovarian stimulation within the last 3 months for ovulation induction or IVF 4. Had evidence of a very low oocyte maturation rate (oocyte maturation rate \< 50% in any previous IVF or IVM cycle). 5. For male partners: severe oligoasthenoteratozoospermia, requirement for retrograde ejaculation procedures or surgical sperm retrievals. Donor sperm is permitted. 6. Known chromosomal abnormalities in participant or partner. 7. Have herself or partner with acute urinary tract infection or sexually transmitted diseases. 8. Have herself or partner a severe mental disorder, such as schizophrenia, bipolar affective disorder, or intellectual disability caused by mental disorders. 9. Have a history of recurrent pregnancy loss defined as two or more clinical pregnancies without live birth. 10. Known tumors of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus that would preclude to conduct a CAPA-IVM cycle without ovarian stimulation or participation in this study. 11. Any known clinically significant systemic disease (heart, liver, kidney or other organs) that would prevent or compromise pregnancy or participation in this study. 12. Pregnancy or contraindication to pregnancy. 13. Undiagnosed vaginal bleeding. 14. Known drug or alcohol abuse or dependency for the participant or partner for the last 12 months. 15. Current or past (3 months) smoking habit of 10 or more cigarettes per day. 16. Had a recent exposure to teratogenic radiation, drugs or toxins which could still be active during the study period. 17. Currently participating in another clinical trial or receiving an investigational medicinal product. 18. Previous participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Assisted reproduction technologies are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aspire Fertility Houston

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.